Johnson & Johnson

NYSE:JNJ  
179.61
+2.10 (+1.18%)
4:24:26 PM EDT: $179.97 +0.36 (+0.20%)
Earnings Announcements, Mergers / Acquisitions

Yumanity Therapeutics To Merge With Kineta In All-Stock Deal

Published: 06/06/2022 10:52 GMT
Johnson & Johnson (JNJ) - Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions.
Yumanity Therapeutics - to Sell Clinical-stage Product Candidate Ytx-7739 & Its Unpartnered Discovery-stage Neuroscience Product Candidates & Targets.
Yumanity - Sale of Ytx-7739 & Unpartnered Discovery-stage Neuroscience Product Candidates and Targets to Janssen Pharmaceutica NV for $26 Million in Cash.
Yumanity Therapeutics Inc - Kineta, Inc., a Private Immuno-oncology Company, to Merge With Yumanity in an All-stock Transaction.
Yumanity - Under Proposed Deal With Janssen, Co Plans to Distribute Any Remaining Available Cash Proceeds to Stockholders Via One-time Dividend.
Yumanity - Combined Publicly Traded Co to Be Re-named Kineta, Inc., That Will Focus on Immuno-oncology, Continue Co's Ongoing Collaboration With Merck.
Yumanity Therapeutics Inc - Current Kineta Stockholders Are Expected to Own Approximately 85% of Combined Company.
Yumanity Therapeutics - Combined Co Expects to Raise Concurrent Private Investment in Public Equity Led by Growth & Value Development Inc.yumanity Therapeutics Inc - Yumanity Board of Directors Has Unanimously Approved Both Definitive Agreements.
Yumanity Therapeutics Inc - Kineta Board of Directors Has Unanimously Approved Definitive Merger Agreement With Yumanity.
Yumanity Therapeutics Inc - Shawn Iadonato, Will Serve As CEO and Craig Philips Will Serve As President of Combined Co.
Revenue is expected to be $23.87 Billion
Adjusted EPS is expected to be $2.57

Next Quarter Revenue Guidance is expected to be $24.17 Billion
Next Quarter EPS Guidance is expected to be $2.66

More details on our Analysts Page.